The perils of inhibiting deficient factors
Essentials Anticoagulation in patients with factor X deficiency is an evidence‐poor area. A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban. Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency. A baseline coagulati...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and haemostasis 2018-08, Vol.16 (8), p.1535-1536 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1536 |
|---|---|
| container_issue | 8 |
| container_start_page | 1535 |
| container_title | Journal of thrombosis and haemostasis |
| container_volume | 16 |
| creator | Sayar, Z. Speed, V. Patel, J. P. Patel, R. K. Arya, R. |
| description | Essentials
Anticoagulation in patients with factor X deficiency is an evidence‐poor area.
A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban.
Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency.
A baseline coagulation screen should be performed prior to commencement of anticoagulation.
Summary
We report a case of a previously undiagnosed factor X deficiency in an 83‐year‐old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban. |
| doi_str_mv | 10.1111/jth.14195 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2052808829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2081322391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3885-3d5481d563d1df3e69c554b50c33faf6a7886a3428ca74c59029f8b1bfb463e63</originalsourceid><addsrcrecordid>eNp10EFLwzAUB_AgipvTg19ACl5U6JbkNV1ylKFOGXiZ55Cmicvo2pm0yL690W4eBN_lvcOPP48_QpcEj0mcybpdjUlGBDtCQ8KAp1MO-fHhFgADdBbCGuNIKD5FAyo4BwzTIbpbrkyyNd5VIWls4uqVK1zr6vekNNZpZ-o2sUq3jQ_n6MSqKpiL_R6ht8eH5WyeLl6fnmf3i1QD5yyFkmWclCyHkpQWTC40Y1nBsAawyuZqynmuIKNcq2mmmcBUWF6QwhZZHjmM0E2fu_XNR2dCKzcuaFNVqjZNFyTFjHLMORWRXv-h66bzdfwuKk6AUhAkqttead-E4I2VW-82yu8kwfK7QBkLlD8FRnu1T-yKjSl_5aGxCCY9-HSV2f2fJF-W8z7yC-YBd24</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2081322391</pqid></control><display><type>article</type><title>The perils of inhibiting deficient factors</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Sayar, Z. ; Speed, V. ; Patel, J. P. ; Patel, R. K. ; Arya, R.</creator><creatorcontrib>Sayar, Z. ; Speed, V. ; Patel, J. P. ; Patel, R. K. ; Arya, R.</creatorcontrib><description>Essentials
Anticoagulation in patients with factor X deficiency is an evidence‐poor area.
A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban.
Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency.
A baseline coagulation screen should be performed prior to commencement of anticoagulation.
Summary
We report a case of a previously undiagnosed factor X deficiency in an 83‐year‐old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/jth.14195</identifier><identifier>PMID: 29883037</identifier><language>eng</language><publisher>England: Elsevier Limited</publisher><subject>Bleeding ; Case reports ; coagulation ; Coagulation factors ; factor X ; Fibrillation ; Hemorrhage ; oral anticaogulants ; pharmacotherapeutics ; rivaroxaban ; Warfarin</subject><ispartof>Journal of thrombosis and haemostasis, 2018-08, Vol.16 (8), p.1535-1536</ispartof><rights>2018 International Society on Thrombosis and Haemostasis</rights><rights>2018 International Society on Thrombosis and Haemostasis.</rights><rights>Copyright © 2018 International Society on Thrombosis and Haemostasis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3885-3d5481d563d1df3e69c554b50c33faf6a7886a3428ca74c59029f8b1bfb463e63</citedby><cites>FETCH-LOGICAL-c3885-3d5481d563d1df3e69c554b50c33faf6a7886a3428ca74c59029f8b1bfb463e63</cites><orcidid>0000-0003-4197-8294 ; 0000-0001-8838-9257</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29883037$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sayar, Z.</creatorcontrib><creatorcontrib>Speed, V.</creatorcontrib><creatorcontrib>Patel, J. P.</creatorcontrib><creatorcontrib>Patel, R. K.</creatorcontrib><creatorcontrib>Arya, R.</creatorcontrib><title>The perils of inhibiting deficient factors</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Essentials
Anticoagulation in patients with factor X deficiency is an evidence‐poor area.
A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban.
Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency.
A baseline coagulation screen should be performed prior to commencement of anticoagulation.
Summary
We report a case of a previously undiagnosed factor X deficiency in an 83‐year‐old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban.</description><subject>Bleeding</subject><subject>Case reports</subject><subject>coagulation</subject><subject>Coagulation factors</subject><subject>factor X</subject><subject>Fibrillation</subject><subject>Hemorrhage</subject><subject>oral anticaogulants</subject><subject>pharmacotherapeutics</subject><subject>rivaroxaban</subject><subject>Warfarin</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp10EFLwzAUB_AgipvTg19ACl5U6JbkNV1ylKFOGXiZ55Cmicvo2pm0yL690W4eBN_lvcOPP48_QpcEj0mcybpdjUlGBDtCQ8KAp1MO-fHhFgADdBbCGuNIKD5FAyo4BwzTIbpbrkyyNd5VIWls4uqVK1zr6vekNNZpZ-o2sUq3jQ_n6MSqKpiL_R6ht8eH5WyeLl6fnmf3i1QD5yyFkmWclCyHkpQWTC40Y1nBsAawyuZqynmuIKNcq2mmmcBUWF6QwhZZHjmM0E2fu_XNR2dCKzcuaFNVqjZNFyTFjHLMORWRXv-h66bzdfwuKk6AUhAkqttead-E4I2VW-82yu8kwfK7QBkLlD8FRnu1T-yKjSl_5aGxCCY9-HSV2f2fJF-W8z7yC-YBd24</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Sayar, Z.</creator><creator>Speed, V.</creator><creator>Patel, J. P.</creator><creator>Patel, R. K.</creator><creator>Arya, R.</creator><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4197-8294</orcidid><orcidid>https://orcid.org/0000-0001-8838-9257</orcidid></search><sort><creationdate>201808</creationdate><title>The perils of inhibiting deficient factors</title><author>Sayar, Z. ; Speed, V. ; Patel, J. P. ; Patel, R. K. ; Arya, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3885-3d5481d563d1df3e69c554b50c33faf6a7886a3428ca74c59029f8b1bfb463e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bleeding</topic><topic>Case reports</topic><topic>coagulation</topic><topic>Coagulation factors</topic><topic>factor X</topic><topic>Fibrillation</topic><topic>Hemorrhage</topic><topic>oral anticaogulants</topic><topic>pharmacotherapeutics</topic><topic>rivaroxaban</topic><topic>Warfarin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sayar, Z.</creatorcontrib><creatorcontrib>Speed, V.</creatorcontrib><creatorcontrib>Patel, J. P.</creatorcontrib><creatorcontrib>Patel, R. K.</creatorcontrib><creatorcontrib>Arya, R.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sayar, Z.</au><au>Speed, V.</au><au>Patel, J. P.</au><au>Patel, R. K.</au><au>Arya, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The perils of inhibiting deficient factors</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2018-08</date><risdate>2018</risdate><volume>16</volume><issue>8</issue><spage>1535</spage><epage>1536</epage><pages>1535-1536</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Essentials
Anticoagulation in patients with factor X deficiency is an evidence‐poor area.
A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban.
Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency.
A baseline coagulation screen should be performed prior to commencement of anticoagulation.
Summary
We report a case of a previously undiagnosed factor X deficiency in an 83‐year‐old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban.</abstract><cop>England</cop><pub>Elsevier Limited</pub><pmid>29883037</pmid><doi>10.1111/jth.14195</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0003-4197-8294</orcidid><orcidid>https://orcid.org/0000-0001-8838-9257</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-7933 |
| ispartof | Journal of thrombosis and haemostasis, 2018-08, Vol.16 (8), p.1535-1536 |
| issn | 1538-7933 1538-7836 1538-7836 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2052808829 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Bleeding Case reports coagulation Coagulation factors factor X Fibrillation Hemorrhage oral anticaogulants pharmacotherapeutics rivaroxaban Warfarin |
| title | The perils of inhibiting deficient factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A06%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20perils%20of%20inhibiting%20deficient%20factors&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=Sayar,%20Z.&rft.date=2018-08&rft.volume=16&rft.issue=8&rft.spage=1535&rft.epage=1536&rft.pages=1535-1536&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/jth.14195&rft_dat=%3Cproquest_cross%3E2081322391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2081322391&rft_id=info:pmid/29883037&rfr_iscdi=true |